Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial

Table 1

Demographic and baseline characteristics of patients.

Characteristic	Treatment group (n = 90)	Control group (n = 90)	P
Age (years)^†	56.74±8.43	55.24±10.83	0.301
Male (%)	78(86.67)	71(78.89)	0.257
Duration of illness (year)^†	3.91±1.31	3.70±1.16	0.236
HBsAg positive (%)	76(84.44)	71(80.90)	0.060
Child–Pugh score			0.083
A	48(53.33)	37(41.11)
B	42(46.67)	53(58.89)
Total bilirubin (μmol/L)^†	17.51±11.24	16.07±8.91	0.387
Albumin (g/L)^†	39.96±4.69	46.35±44.97	0.161
ALT (IU/L)^†	51.08±42.74	53.01±37.06	0.683
AST (IU/L)^†	47.56±42.05	52.14±39.37	0.815
α-fetoprotein (ng/mL)^†	307.82±257.58	275.23±141.07	0.484
ECOG score			0.362
0	29(32.22)	27(30.0)
1	54(60.0)	60(66.67)
2	7(7.78)	3(3.33)
Type of treatment			0.357
HR	22(24.44)	18(20.0)
RFA	7(7.78)	8(8.89)
MWA	6(6.67)	5(5.56)
PEI	4(4.44)	2(2.22)
TACE	51(56.67)	57(63.33)

Notes: values in parentheses are percentages; ^†value is the mean ± standard deviation.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, Eastern Cooperative Oncology Group; HR, hepatic resection; RFA, radiofrequency ablation; MWA, microwave ablation; PEI, percutaneous ethanol injection; TACE, transcatheter arterial chemoembolization.